304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2024-09-09

Latest Results of Serplulimab in the Field of SCLC Released at 2024 WCLC
2024-09-02

IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA
2024-08-26

Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1
2024-08-22

Henlius Trastuzumab Receives Approval in Canada
2024-08-20

Henlius and Convalife Reach Global Strategic Cooperation on Neratinib
2024-08-08

First Patient Dosed of Phase 2 Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein in Combination with Serplulimab Plus HANBEITAI for the First-line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients
2024-08-07

Henlius to Release Latest Results of HANSIZHUANG and HANQUYOU at ESMO Congress 2024
2024-08-05

Henlius to Showcase Latest Results of Serplulimab in the Field of Lung Cancer at 2024 WCLC
2024-07-26

HANQUYOU launched for 4 years with international quality recognized worldwide